FilingSEC EDGAR8-K
Adicet Bio Updates Pipeline Development Status via Corporate Presentation
· SEC accepted
StageClinical and Research Stage
Filing content
Adicet Bio posted a corporate presentation to its website detailing the clinical development status and upcoming milestones for its key pipelines, including prula-cel and ADI-212.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…